VEGFA and liver dysplastic nodule: Arctigenin has been reported to mitigate these effects by concurrently inhibiting PDGF-BB and Vascular endothelial growth factor (VEGF), key mediators of critical regulators of mesangial proliferation and glomerular hyperpermeability in DN [57,67,68].